OCGN
ocgn-20200603xex991 Our Mission is to develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck Forward Looking Statement This presentation contains forward-looking statements that involve substantial BiopharmaWatch Research Key Takeaway: Our Mission is to develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck
Breakthrough Modifier Gene Therapy Platform Addressing Multiple Diseases with One Product 6
OCU200: Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Wet AMD Novel Biologic Offe
BiopharmaWatch Analysis From our catalyst data and publicly available data · not financial advice Best trade, last catalyst
+79%
120-day peak, hindsight
Typical move
3.6%
average across 4 past catalysts
Cash runway
~24 mo
Low dilution risk
Lead asset
OCU200
Phase 1 · Center Involved Diabetic Macular Edema
Full Press Release Details Our Mission is to develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck
Breakthrough Modifier Gene Therapy Platform Addressing Multiple Diseases with One Product 6
OCU200: Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Wet AMD Novel Biologic Offering Benefits Beyond Anti-VEGF 18
A Bold Vision to Cure Blindness Diseases with Gene Therapies For more information, contact: Kelly Beck Vice President, Investor Relations & Administration
kelly.beck@ocugen.com Tags: OCGN Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare